Salesforce (CRM) is expanding its presence with full force. The company recently announced two partnerships, one with Takeda, a global biopharmaceutical company, and another with the U.S. General Services Administration (GSA), provider of contracting options for government agencies.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Both deals increase Salesforce’s market reach, driving higher adoption of its AI and cloud solutions across the healthcare and government sectors.
Key Details About the Deals
Takeda is using Salesforce’s Life Sciences Cloud for Customer Engagement to simplify communication with doctors and patients. The platform uses AI insights, real-time data, and digital tools to improve support in medical, business, and patient care areas.
By adopting CRM’s Agentforce and Data Cloud, Takeda aims to improve provider engagement, speed up clinical trial recruitment, and help patients stay on treatment with AI automation.
On the same day, Salesforce collaborated with the GSA to provide Slack, a cloud-based team communication platform, at a much lower price to federal agencies. The partnership will introduce AI-driven automation, data unification, and cloud-based solutions to streamline citizen interactions and government workflows.
Top Analyst Bullish on CRM Stock
Recently, a five-star analyst, Patrick Walravens from Citizens JMP, reaffirmed a Buy rating for Salesforce stock with a $430 price target, which implies 50% upside potential.
The analyst cited Salesforce’s new flexible pricing for Agentforce, introduced on May 15, as a key factor in maintaining confidence in the stock.
Is CRM a Buy, Hold, or Sell?
Turning to Wall Street, CRM stock has a Moderate Buy consensus rating based on 31 Buys, eight Holds, and three Sells assigned in the last three months. At $357.08, the average Salesforce stock price target implies a 24.15% upside potential.
